Phase 4Recruiting

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (CLIgAN)

Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Sponsor
Fondazione Schena (Academic or other)
Enrollment
878 planned
Conditions
Glomerulonephritis; Immunoglobulin A Nephropathy
Interventions
Corticosteroid; Renin-angiotensin sytem blockers; Sodium-glucose cotransporter 2 inhibitor
Ages
adults, older adults
Registry
NCT04662723

Full record on ClinicalTrials.gov

From the registry

Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy. The high prevalence of ESKD suggests the need to move from a generalized therapy for all patients to personalized therapy. Many RCTs have been conducted stratifying patients based on the laboratory findings (serum creatinine, eGFR and daily proteinuria). In contrast, data from the kidney biopsy has been used only for clinical diagnosis. Therefore, IgAN patients with active or chronic renal lesions have not been equally distributed in experimental and control arms of the randomized clinical trials (RCTs) Our clinical study of IgAN (CLIgAN) is a multicentre, prospective, controlled and open-label randomized clinical trial based on patients' stratification at the time of their kidney biopsy. The investigators will consider, first, the type of renal lesions followed by the serum creatinine values, eGFR and proteinuria. IgAN patients with active renal lesions (n=132)…

Primary outcomes

  • -Proteinuria reduction within 6 months in IgAN patients with active renal lesions
  • Proteinuria reduction within 6 months in IgAN patients with active renal lesions
  • Proteinuria reduction within 6 months in IgAN patients with chronic renal lesions
  • Proteinuria reduction within 6 months in IgAN with chronic renal lesions

History

  1. Study completion expected

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered

Papers citing this trial